Tessera Therapeutics

Tessera Therapeutics

Private
Somerville, MassachusettsHealthcare & Life Scienceshttps://www.tesseratherapeutics.com

Last Round

Grant

3/23/2026

Total Funding Raised

$621.3M

Momentum Score

25 /100

Company Overview

Tessera (Biotechnology) is a genetic engineering company that develops gene writing technology to facilitate permanent modifications to the human genome for therapeutic purposes.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

gene writinggene editinggenetic medicinemobile genetic elementsMGEsRNA gene writersDNA gene writerslipid nanoparticlesLNPsnon-viral deliverygene therapytherapeutic pipelinedrug developmentbiopharma partnershipsAATD therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tessera Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Tessera Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Grant3/23/2026
Strategic12/18/2024
Series C4/19/2022
Series B1/12/2021
Series A7/7/2020

Key People

Founding team and executive leadership

Geoffrey von Maltzahn

Founding CEO, Chairman Of Board

Founding Team

Michael Severino

Chief Executive Officer

Executive Team

Howard Liang

President And CFO

Executive Team

Kathy Bergsteinsson

Chief Financial Officer

Executive Team

Tessera Therapeutics Investors

Notable investors and investment history

InvestorRounds
SoftBank Investment AdvisersSeries B
SALT FundSeries C
Altitude Life Science VenturesSeries C, Series B
SoftBank Vision Fund 2Series C, Series B
ARTIS VenturesSeries C
Alaska Permanent FundSeries C, Series B
Bill & Melinda Gates FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 23, 2026

    $41.3M raised in grant funding.

  • Mar 23, 2026

    Developing curative in vivo genetic treatment for sickle cell disease.

Tessera Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tessera Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tessera Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSomerville, Massachusetts
Employee Range257
Year Founded2017
Last Funding3/23/2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.